| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* National Cancer Institute, Bethesda, MD 20892;
Torrey Pines Institute for Molecular Studies, San Diego, CA 92121; and
National Institute of Neuroscience, Tokyo, Japan
Negative immunoregulation is a major barrier to successful cancer immunotherapy. The NKT cell is known to be one such regulator. In this study we explored the roles of and interaction between the classical type I NKT cell and the poorly understood type II NKT cell in the regulation of tumor immunity. Selective stimulation of type II NKT cells suppressed immunosurveillance, whereas stimulation of type I NKT cells protected against tumor growth even when responses were relatively skewed toward Th2 cytokines. When both were stimulated simultaneously, type II NKT cells appeared to suppress the activation in vitro and protective effect in vivo of type I NKT cells. In the absence of type I, suppression by type II NKT cells increased, suggesting that type I cells reduce the suppressive effect of type II NKT cells. Thus, in tumor immunity type I and type II NKT cells have opposite and counteractive roles and define a new immunoregulatory axis. Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was partially supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, and Center for Cancer Research.
2 Address correspondence and reprint requests to Dr. Masaki Terabe, Vaccine Branch, National Cancer Institute, Building 10, Room 6B-12, 10 Center Drive, National Institutes of Health, Bethesda, MD 20892. E-mail address: terabe{at}mail.nih.gov
3 Abbreviations used in this paper: 
GalCer, -galactosylceramide; WT, wild type.
This article has been cited by other articles:
|
|
 |
|
  R. D. Kuns, E. S. Morris, K. P. A. MacDonald, K. A. Markey, H. M. Morris, N. C. Raffelt, T. Banovic, A. L. J. Don, V. Rowe, A. C. Burman, et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after {alpha}-galactosylceramide administration Blood, June 4, 2009; 113(23): 5999 - 6010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Fujii, A. Goto, and K. Shimizu Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity Blood, April 30, 2009; 113(18): 4262 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Ko, J.-M. Lee, Y.-J. Kim, Y.-S. Kim, K.-A Lee, and C.-Y. Kang Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine J. Immunol., February 15, 2009; 182(4): 1818 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Choi, H. Xu, Y. Geng, A. Colmone, H. Cho, and C.-R. Wang Bacterial infection alters the kinetics and function of iNKT cell responses J. Leukoc. Biol., December 1, 2008; 84(6): 1462 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Peterfalvi, E. Gomori, T. Magyarlaki, J. Pal, M. Banati, A. Javorhazy, J. Szekeres-Bartho, L. Szereday, and Z. Illes Invariant V{alpha}7.2-J{alpha}33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells Int. Immunol., December 1, 2008; 20(12): 1517 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wakao, R. Wakao, S. Sakata, K. Iwabuchi, A. Oda, and H. Fujita In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer FASEB J, July 1, 2008; 22(7): 2223 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, D. Zhou, C. Xia, P. G. Wang, and S. B. Levery Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry Glycobiology, February 1, 2008; 18(2): 166 - 176. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
